NEW YORK (GenomeWeb News) – Microarray diagnostics firm SQI said Monday that it has raised gross proceeds of C$1.5 million (US$1.3 million) through a non-brokered private placement.

The Toronto-based firm placed almost 3 million units at C$.50 per unit, with each unit consisting of one common share and one common share purchase warrant. Each warrant entitles the holder to purchase one common share at a price of C$.65 for two years from the date of issuance.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers suggest that genetic variations could influence the side effects people experience when using synthetic cannabinoids, the International Business Times reports.

An analysis has examined the makeup of researchers on Twitter and what they share, Nature News reports.

At Stat News, Jim Kozubek argues that the Broad Institute is pushing the boundary of what a nonprofit is.

In PNAS this week: gut microbes may affect honeybee weight, phenotype and gene expression changes in DiGeorge syndrome, and more.